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No study has ever examined the eﬀect of 5-HT7 receptor agonists on nociception by using 5-HT7 receptor knockout mice. Basal
sensitivity to noxious heat stimuli and formalin-induced nociception in both phase I and II of the formalin test did not diﬀer in 5-
HT7 receptorknockoutmiceandpairedwild-typecontrols.Similarly,therewasnosigniﬁcantdiﬀerenceinbasalbodytemperature
between both genotypes. Subcutaneous administration of 5-HT7 receptor agonists AS-19 (10mg/kg), E-57431 (10mg/kg), and E-
55888 (20mg/kg) signiﬁcantly reduced formalin-induced licking/biting behavior during the phase II of the test in wild-type but
not in 5-HT7 receptor knockout mice. At these active analgesic doses, none of the three 5-HT7 receptor agonists modiﬁed the basal
body temperature neither in wild-type nor in 5-HT7 receptor knockout mice. However, a signiﬁcant decrease in body temperature
was observed at a higher dose (20mg/kg) of AS-19 and E-57431 in both genotypes. Our data strongly suggest that the 5-HT7
receptor agonists AS-19, E-57431, and E-55888 produce antinociception in the formalin test by activating 5-HT7 receptors. These
results also strengthen the idea that the 5-HT7 receptor plays a role in thermoregulation, but by acting in concert with other
receptors.
1.Introduction
The 5-HT7 receptor has been cloned from diﬀerent genomes
and its binding proﬁle is consistent across species and
between cloned and native receptors [1, 2]. In recent years,
considerable eﬀorts have focused on the development of
selective 5-HT7 receptor agonists and antagonists. To date,
the search for 5-HT7 receptor antagonists has led to the
discovery of LY215840 [3], SB-258719 [4], DR4004 [5], SB-
269970 [6], and SB-656104-A [7]. Regarding 5-HT7 receptor
agonists, AS-19 [8, 9], MSD-5a [10], LP-44 [11], LP-211
[12], E-55888 [13], and E-57431 [14] have been developed.
However, most of these agonists display rather modest
selectivitybecausetheiraﬃnityforthe5-HT7 typeisonly11-
fold higher than for 5-HT1D in case of AS-19 [13], 28.6-fold
higher than for 5-HT1A in case of MSD-5a [10], and 33-fold
higher than for dopamine D2 receptor [15], and 5-14-fold
higherthanfor5-HT1B,5-HT2B,5-HT2C,and5-HT5A incase
ofLP-211 [16].Indeed, among5-HT7 receptoragonists, only
E-55888 and E-57431 seem to have a satisfactory selectivity
with aﬃnity for the 5-HT7 receptor 280-fold higher than for
5-HT1A and 112.7-fold higher than for 5-HT1D,r e s p e c t i v e l y
[13] (see Table 1). When tested in a functional assay, 5-
HT7 receptor agonists concentration dependently increased
cAMPformationinHEK-293F/h5-HT7 cells.AS-19hasbeen
found to behave as a potent (EC50 = 9 ± 1nM) but partial 5-
HT7 receptor agonist, with a maximal eﬀect reaching 77%
of that of 5-HT [13]. However, E-55888 and E-57431 behave
as full agonists, with eﬃcacies (Emax = 99 ± 1% and 94.5 ±
1%, resp.) and potencies (EC50 = 16 ± 1nM and 21.5 ±
1nM) similar to those of 5-HT, as previously described
[13, 14].2 Advances in Pharmacological Sciences
Table 1: Binding proﬁles of the 5-HT7 receptor agonists AS-19, E-57431, and E-55888.
Receptor Aﬃnity (Ki (nM))
AS-19 E-57431 E-55888
h5-HT1A 89.7 (149.5 x) n.s. 700 (280 x)
r5-HT1B 490 (816.6 x) n.s. n.s.
h5-HT1D 6.6 (11 x) 53 (112.7 x) n.s.
h5-HT2A n.s. 560 (1191.5 x) n.s.
h5-HT2B n.s. n.s. n.s.
h5-HT2C n.s. n.s. n.s.
h5-HT3 n.s. n.s. n.s.
h5-HT4e — n.s. n.s.
gp5-HT4 n.s. n.s. —
h5-HT5A 98.5 (164.2 x) n.s. n.s.
h5-HT6 n.s. n.s. n.s.
h5-HT7 0.6 0.47 2.5
h5-HT transporter (SERT) n.s. n.s. n.s.
Other receptors n.s.a n.s.b n.s.a
n.s.: not signiﬁcant (Ki > 1 μM or less than 50% inhibition of speciﬁc radioligand binding at 1 μM);
—: data not available.
gp: guinea pig; h: human; r: rat.
Data obtained from Brenchat et al. [13, 14]
Data in parentheses after Ki values represent the aﬃnity ratio versus 5-HT7 r e c e p t o r sc a l c u l a t e da sK i for the tested receptor/Ki for 5-HT7 receptor. It is
expressed as number-fold higher (x) for 5-HT7 than for the tested receptor.
aSee the panel of other receptors assayed [13].
bSee the panel of other receptors assayed [14].
From data obtained with these pharmacological tools,
it has been claimed that 5-HT7 receptors are involved in a
number of physiological and pathophysiological phenomena
such as nociception and thermoregulation. Data supporting
a role for 5-HT7 receptors in pain control mostly suggest
an antinociceptive eﬀect of 5-HT7 receptor activation in
the CNS and, in contrast, a pronociceptive eﬀect of 5-HT7
receptor activation in the periphery [17–23]. However, an
overall antinociceptive eﬀect has been observed following
systemic administration of the selective 5-HT7 receptor
agonists AS-19, E-57431, and E-55888 to rodents suﬀering
from neuropathic pain [13, 14].
On the other hand, 5-HT7 r e c e p t o r sh a v eb e e ni n v o l v e d
in the control of body temperature based on studies using
some 5-HT7 receptor agonists (5-CT, 8-OH-DPAT, and
LP-211), 5-HT7 receptor antagonists (SB-258719 and SB-
269970) and 5-HT7 receptor knockout mice. Activation
of 5-HT7 receptors has been reported to decrease body
temperature in a complex manner, in concert with other
serotonergic receptors such as the 5-HT1A receptor and/or
nonserotonergic receptors [16, 24–28].
In addition to pharmacological studies using 5-HT7
receptor agonists and antagonists, the 5-HT7 receptor
knockout mice may provide a relevant tool to explore the
functions of this receptor, and to assess the speciﬁcity of
ligands supposed to interact selectively with it. Accordingly,
the present study examines the eﬀects of the so-called 5-
HT7 receptor agonists AS-19, E-57431, and E-55888 on
formalin-induced pain behavior and thermoregulation in 5-
HT7 receptorknockoutandpairedwild-typemiceinorderto
determine the in vivo functional selectivity of these ligands at
this speciﬁc receptor type.
2.MaterialsandMethods
2.1. Animals. Male, 5- to 8-week-old, 5-HT7 receptor
knockout (5-HT7R−/−) C57BL/6J mice and their wild-
type 5-HT7R+/+ siblings used in this study were provided
by Deltagen (CA, USA). Embryonic stem cells derived
from the 129/OlaHsd mouse substrain were used to
generate chimeric mice. F1 mice were generated by
breeding with C57BL/6 females. F2 homozygous mutant
mice were produced by intercrossing F1 heterozygous
males and females. Successive mating of heterozygous
progeny to the inbred C57BL/6J strain was performed
for at least 8 generations before the knockout and wild-
type homozygous oﬀsprings were used in the present
study. Genotyping was performed by PCR analysis
using a protocol described by The Jackson Laboratory
(http://jaxmice.jax.org/protocolsdb/f?p=116:2:24205673177
16723::NO:2:P2 MASTER PROTOCOL ID,P2 JRS CODE:
1854,005769). Animals were housed in groups of ﬁve,
provided with food and water ad libitum and kept in
controlled laboratory conditions with ambient temperature
maintained at 21 ± 1◦Ca n dl i g h ti n1 2 hc y c l e s( o na t
07:00h and oﬀ at 19:00h). Experiments were carried out
in a sound-attenuated, air-regulated, experimental room.
All experimental procedures and animal husbandry were
conducted according to ethical principles for the evaluation
ofpaininconsciousanimals[29],andtoethicalguidelinesof
the European Communities Council Directive of NovemberAdvances in Pharmacological Sciences 3
24, 1986 (86/609/EEC). The experimental work received
approval by the Local Ethical Committee.
2.2. Drugs. Formaldehyde (37wt.% solution) was purchased
from Panreac (Spain) and dissolved in physiological saline.
Drugs used for treatments were AS-19 (dimethyl-[5-(1,3,5-
tri-methyl-1H-pyrazol-4-yl)-1,2,3,4-tetrahydro-naphthalen-
2(S)-yl]-amine) [8, 9], E-55888 (dimethyl-{2-[3-(1,3,5-
trimethyl-1H-pyrazol-4-yl)-phenyl]-ethyl}-amine dihydro-
chloride) [13], and E-57431 (2-(2-(dimethylamino)ethyl)-
4-(1,3,5-tri-methyl-1H-pyrazol-4-yl)phenol) [14]. AS-19 is
a potent selective 5-HT7 receptor agonist commercially
available from Tocris Bioscience (UK), whereas E-55888
and E-57431 are 5-HT7 receptor agonists developed by
ESTEVE Laboratories (Barcelona, Spain). All three 5-HT7
receptor agonists were synthesized for the purpose of this
study at ESTEVE, dissolved in aqueous solutions containing
0.5% (hydroxypropyl) methyl cellulose (Sigma-Aldrich,
Spain) and administered in a volume of 5ml/kg through
the subcutaneous (s.c.) route. Doses of drugs (referred to
their salt forms) and time of evaluation were selected based
on previous studies [13, 14] and on pilot experiments in
models used in this study. All treatments were performed
under blind conditions in independent groups of mice
and behavioral evaluation was done 30min after drug
administration.
2.3. Nociceptive Behavioral Tests
2.3.1. Tail Flick Test. Animals were placed in a loose plexiglas
restrainer with their tail extruding through a hole to perform
the tail ﬂick test as previously described [30]. A photobeam
was placed on the tail about 4cm from the tip. The latency to
tail ﬂick response was recorded automatically to the nearest
0.1s. The intensity of the radiant heat source was adjusted to
yield baseline latencies between 3 and 5s in wild-type mice.
A cut-oﬀ latency of 10s was imposed to avoid damage of tail
tissues.
2.3.2. Tail Immersion Test. Animals were placed in a loose
plexiglas restrainer with their tail extending through a hole
in the water bath of the apparatus (Stuart Bibby Sterilin Ltd,
Water Baths SWB1D, UK), as previously described [31]. The
lower2/3ofthetailwasimmersedinhotwatermaintainedat
a constant temperature of 52.0 ± 0.5◦C. The latency between
tail immersion and attempts to remove the tail from the
hot water bath was recorded. A cut-oﬀ latency of 15s was
imposed to avoid damage of tail tissues.
2.3.3.HotPlateTest. Animalswereplacedindividuallyonthe
surface of the hot plate apparatus (PanLab, LE 7406, Spain)
surrounded by a plexiglas cylinder (20cm in diameter, 25cm
high). The temperature of the surface was maintained at 55.0
± 0.5◦C, according to the method previously described [32].
The time between placement and the occurrence of forepaw
licking (FPL), hindpaw licking (HPL), or jump was recorded
as response latency. A cut-oﬀ latency of 240s was established
to avoid damage of paw tissues.
2.3.4. Formalin Test. Formalin (20μL of a 2.5% formalin
solution; 0.92% of formaldehyde) was injected into the
dorsal surface on the right hind paw, as previously described
[33]. The formalin test is a valid and reliable model of
nociception with two distinct periods of high licking activity
that have diﬀerent nociceptive mechanisms, an early phase
lasting the ﬁrst 5min and a late phase lasting from 15 to
45min after the injection of formalin. Mice were placed on
a paper surface surrounded by a plexiglas cylinder (20 ×
25cm) and the time spent licking and biting the injected
paw was measured using a chronometer. A time course of the
licking/biting behaviors was monitored during 45 minutes
after formalin injection to evaluate possible diﬀerences
b e t w e e ng e n o t y p e s .D r u ge ﬀects were quantiﬁed at 0–5min
(phase I) and 15–30min (phase II) after formalin injection,
two periods of time in which the formalin-induced licking
and biting time was high enough to test antinociceptive
eﬀects of drugs.
2.3.5. Rectal Temperature. The body temperature was
recorded using a precision thermometer (YSI 4600)
equipped with a ﬂexible probe (YSI 402). This probe was
lubricated with vaseline and inserted 2cm into the rectum.
Temperature recordings were made 20s following insertion
of the probe, as previously described [27, 28].
2.4. Data Analysis. Data are presented as mean values ±
S.E.M. Statistical analysis to test signiﬁcant diﬀerences
among groups was made using ANOVA followed by Bon-
ferroni’s post hoc comparison. Unpaired Student’s t-test was
used to test diﬀerences between two groups. The level of
signiﬁcance was set at P<0.05. Data analysis and graphing
were done using GraphPad Prism software (version 4.0;
GraphPad Software Inc., USA).
3. Results
3.1. Similar Response to Noxious Thermal Stimuli and
Formalin-Induced Nociception in 5-HT7 Receptor Knockout
and Wild-Type Mice. Sensitivity to noxious heat measured
as the latency of response to thermal stimulation in the
tail ﬂick, tail immersion, and hot plate tests was similar
in 5-HT7 receptor knockout mice and paired wild-type
mice (Figure 1). No signiﬁcant diﬀerences between the two
genotypes were found in tail withdrawal latency in the tail
ﬂick (t49 = 1.09, P = 0.28) and tail immersion (t49 = 1.82,
P = 0.08)tests(Figure 1(a)).Bothgenotypesshowedalsothe
same latency for all measured behaviors in the hot plate test
(Figure 1(b)):forepawlicking(t49 =1.69,P = 0.10),hindpaw
licking(t49 =0.73,P = 0.47),andjump(t48 =0.81,P = 0.42),
suggesting that 5-HT7 receptor knockout mice perceive and
respond normally to acute thermal nociceptive stimuli. In
addition, formalin-induced licking and biting of the paw
injected with formalin in 5-HT7 receptor knockout mice did
not diﬀer from wild-type mice. Repeated measures ANOVA
(time×genotype)showedasigniﬁcanteﬀectoftime(F8,162 =
24.30, P<0.001), but no eﬀect of genotype (F1,162 = 1.76,
P = 0.19) and no interaction between these two factors4 Advances in Pharmacological Sciences
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Figure 1: Nociceptive behavior of wild-type and 5-HT7 receptor knockout mice in the tail ﬂick and tail immersion tests (a), hot plate 55◦C
test (b), and formalin test (c). Both genotypes showed similar latency for all measured behaviors in the tail ﬂick, tail immersion, and hot
platetests.Formalin-inducedlickingandbitingofthehindpawinjectedwithformalinin5-HT7 receptorknockoutmicedidnotsigniﬁcantly
diﬀer from those in wild-type mice either in phase I (0–5min) or in phase II (15–45min). Only a slight but not signiﬁcant increase of the
licking/biting time was observed 25 min after formalin injection in 5-HT7 receptor knockout mice compared to wild-type mice. Each bar or
symbol represents the mean ± S.E.M. (n = 10–12 per group). Forepaw licking: FPL; hindpaw licking: HPL. No signiﬁcant diﬀerences were
observed in thermal nociception (unpaired Student’s t-test) or formalin-induced nociceptive behaviors (Two-Way ANOVA).
(F8,162 = 0.90, P = 0.52). A slightlygreaterlicking/biting time
was observed 25min after formalin injection in the 5-HT7
receptor knockout in comparison with wild-type mice, but
diﬀerence was not signiﬁcant (Figure 1(c)).
3.2. 5-HT7 Receptor Agonists Inhibited Selectively Phase II of
Formalin-Induced Nociceptive Behavior in Wild-Type but Not
in 5-HT7 Receptor Knockout Mice. To examine the in vivo
functional speciﬁcity of 5-HT7 receptor agonists, AS-19, E-
57431 and E-55888 were subcutaneously administered to
wild-type and 5-HT7 receptor knockout mice, and treated
animals were then subjected to nociceptive tests. Eﬀective
dosesofAS-19(10mg/kg),E-57431(10mg/kg),andE-55888
(20mg/kg) in reversing allodynia/hyperalgesia following
capsaicin sensitization and nerve injury [13, 14] were used
in these experiments. The 5-HT7 receptor agonists were
administered in the formalin test at doses devoid of motor
disturbing eﬀects which could interfere with licking/biting
behaviors, as previously described [14].
No signiﬁcant eﬀects were exerted by 5-HT7 receptor
agonists on the response to thermal stimuli in the tail ﬂick,
tailimmersion,andhotplatetests,andtheformalin-induced
p h a s eIn o c i c e p t i v eb e h a v i o rw a sn o tm o d i ﬁ e dw h e n5 -
HT7 receptor agonists were administered to wild-type or 5-
HT7 receptor knockout mice (data not shown). However,
all three 5-HT7 receptor agonists inhibited phase II of the
formalin-induced nociceptive behavior in wild-type mice, as
evidenced by a reduction in the duration of licking/biting
of the hindpaw injected with formalin (Figure 2). Two-
way ANOVA (treatment × genotype) showed a signiﬁcant
eﬀect of treatment after AS-19 administration (F1,38 =
10.34, P = 0.003), without genotype eﬀect (F1,38 = 0.04,Advances in Pharmacological Sciences 5
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Figure 2: Eﬀects of 5-HT7 receptor agonists AS-19 (a), E-57431 (b), and E-55888 (c) on formalin-induced nociceptive behaviors during
phase II in wild-type and 5-HT7 receptor knockout mice. Subcutaneous administration of AS-19 (10mg/kg), E-57431 (10mg/kg), and E-
55888 (20mg/kg) signiﬁcantly reduced the licking/biting time of the hind paw injected with formalin in wild-type but not in 5-HT7 receptor
knockout mice. Each bar represents the mean ± S.E.M. (n = 7–12). ∗∗∗P<0.001 versus vehicle corresponding group; ##P<0.01 versus
corresponding dose in 5-HT7 receptor knockout mice (Bonferroni multiple comparison test after ANOVA).
P = 0.84) and a signiﬁcant interaction between these two
factors (F1,38 = 4.86, P = 0.03). The comparison between
treatments revealed a signiﬁcant reduction of licking/biting
time after AS-19 administration at 10mg/kg in wild-type
mice (P<0.001; Figure 2). Two-way ANOVA calculated
for E-57431 also showed a signiﬁcant eﬀect of treatment
after E-57431 administration (F1,39 = 15.04, P < 0.001),
without genotype eﬀect (F1,39 = 2.64, P = 0.11) and a
signiﬁcant interaction between these two factors (F1,39 =
14.91, P<0.001). The comparison between treatments
revealed a signiﬁcant reduction of licking/biting time after
E-57431 administration at 10mg/kg in wild-type mice (P<
0.001; Figure 2). In addition, a signiﬁcant diﬀerence was
found between genotypes when E-57431 was administered
at 10mg/kg (P<0.01; Figure 2). In the same way, two-
way ANOVA calculated for E-55888 also showed a signiﬁcant
eﬀectoftreatmentafterE-55888administration(F1,35 =22.3,
P<0.001), without genotype eﬀect (F1,35 = 2.42, P =
0.13) and a signiﬁcant interaction between these two factors
(F1,35 = 13.32, P<0.001). The comparison between
treatments revealed a signiﬁcant reduction of licking/biting
time after E-55888 administration at 20mg/kg in wild-
type mice (P<0.001; Figure 2). In addition, a signiﬁcant
diﬀerence was found between genotypes when E-55888 was
administered at 20mg/kg (P<0.01; Figure 2). Interestingly,
none of the three 5-HT7 receptor agonists exerted signiﬁcant
eﬀects on formalin phase II nociceptive behavior in 5-HT7
receptor knockout mice (Figure 2).
3.3. Selective Doses of 5-HT7 Receptor Agonists Produced No
Eﬀect on Body Temperature in 5-HT7 Receptor Knockout
and Wild-Type Mice. The in vivo speciﬁcity of the 5-HT7
receptor agonists (AS-19, E-57431, and E-55888) was further
examined using 5-HT7 receptor knockout and paired wild-
type mice in the paradigm based on 5-HT7 receptor-
mediated hypothermia [27]. Basal body temperature did
not signiﬁcantly diﬀer in 5-HT7 receptor knockout and6 Advances in Pharmacological Sciences
37
36
35
34
33
32
31
30
Vehicle 10 mg/kg 20 mg/kg
B
o
d
y
 
t
e
m
p
e
r
a
t
u
r
e
 
(
◦
C
)
∗∗∗
∗∗∗
###
(a) AS-19
Vehicle 10 mg/kg 20 mg/kg
37
36
35
34
33
32
31
30
B
o
d
y
 
t
e
m
p
e
r
a
t
u
r
e
 
(
◦
C
)
∗∗∗
∗∗∗
#
(b) E-5743
Vehicle 20 mg/kg
37
36
35
34
33
32
31
30
B
o
d
y
 
t
e
m
p
e
r
a
t
u
r
e
 
(
◦
C
)
5-HT7R+/+
5-HT7R−/−
(c) E-55888
Figure 3: Eﬀects of 5-HT7 receptor agonists AS-19 (a), E-57431 (b), and E-55888 (c) on body temperature in wild-type and 5-HT7 receptor
knockout mice. Subcutaneous administration of AS-19 and E-57431 at 20mg/kg signiﬁcantly reduced body temperature in both wild-
type and 5-HT7 receptor knockout mice and showed signiﬁcant diﬀerences between both genotypes. However, E-55888 at 20mg/kg did
not reduce the body temperature neither in wild-type nor in 5-HT7 knockout mice. Each bar represents the mean ± S.E.M. (n = 8–12).
∗∗∗P<0.001 versus vehicle corresponding group; #P<0.05; ###P<0.001 versus corresponding dose in 5-HT7 receptor knockout mice
(Bonferroni multiple comparison test post-ANOVA).
paired wild-type mice (36.1 ± 0.1◦Ca n d3 5 .8 ± 0.1◦C, resp.;
Figure 3).
Two-way ANOVA (treatment × genotype) showed a
signiﬁcant eﬀect of treatment after AS-19 administration
(F2,49 = 62.17, P<0.001), with genotype eﬀect (F1,49 = 6.88,
P = 0.01) and a signiﬁcant interaction between these two
factors (F2,49 = 4.77, P = 0.01). The comparison between
treatments revealed a signiﬁcant reduction of body temper-
ature after AS-19 administration at 20mg/kg in wild-type
and 5-HT7 receptor knockout mice (P<0.001; Figure 3).
In addition, a signiﬁcant diﬀerence was found between
genotypes when AS-19 was administered at 20mg/kg (P<
0.001; Figure 3). Two-way ANOVA calculated for E-57431
also showed a signiﬁcant eﬀect of treatment after E-57431
administration (F2,49 = 35.85, P<0.001), without genotype
eﬀect (F1,49 = 0.31, P = 0.58) and a signiﬁcant interaction
between these two factors (F2,49 = 5.82, P = 0.005).
The comparison between treatments revealed a signiﬁcant
reduction of body temperature after E-57431 administration
at 20mg/kg in wild-type and 5-HT7 receptor knockout mice
(P<0.001;Figure 3).Inaddition,asigniﬁcantdiﬀerencewas
foundbetweengenotypeswhenE-57431 wasadministered at
20mg/kg (P<0.05; Figure 3). However, two-way ANOVA
calculated for E-55888 did not show signiﬁcant diﬀerences
on treatment after E-55888 administration (F1,35 = 0.02, P =
0.89), neither genotype eﬀect (F1,35 = 0.91, P = 0.35) nor
interactionbetweenthesetwofactors(F1,35 =0.21,P = 0.65).
The comparison between treatments and genotypes did not
reveal signiﬁcant reduction of body temperature after E-
55888 administration at 20mg/kg (P>0.05; Figure 3).
Subcutaneous administration of doses of AS-19
(10mg/kg), E-57431 (10mg/kg), and E-55888 (20mg/kg)
which exerted analgesic eﬀects in phase II formalin-induced
pain, did not signiﬁcantly change body temperature
neither in 5-HT7 receptor wild-type nor in knockout
mice (Figure 3). However, administration of a higher doseAdvances in Pharmacological Sciences 7
(20mg/kg, s.c.) of the 5-HT7 receptor agonists AS-19
and E-57431 signiﬁcantly reduced body temperature in
both genotypes (Figure 3), suggesting that at such a high
dose the selectivity window of AS-19 and E-57431 was
overstepped. AS-19 at the 20mg/kg dose produced a higher
body temperature reduction in wild-type than in 5-HT7
receptor knockout mice (3.8 versus 2.4◦C, resp.). In contrast,
E-57431 at the same high dose (20mg/kg) produced a lower
body temperature reduction in wild-type than in 5-HT7
receptor knockout mice (1.1 versus 2.3◦C, resp.) (Figure 3).
4. Discussion
In this study, the in vivo target-speciﬁc eﬀects of the 5-HT7
receptor agonists AS-19, E-57431, and E-55888 on nocicep-
tion (i.e., formalin-induced nociception) and thermoregu-
lation were examined using 5-HT7 receptor knockout mice.
These5-HT7 receptoragonistsexertedantinociceptiveeﬀects
in phase II of the formalin test in wild-type but not in 5-
HT7 receptor knockout mice, suggesting that their analgesic
eﬀect is actually 5-HT7 receptor mediated. Analgesic doses
of 5-HT7 receptor agonists did not change body temperature
neither in 5-HT7 receptor knockout nor in wild-type mice.
However, a reduction in body temperature was observed in
both genotypes when the dose of the agonists were increased
up to levels exceeding their selectivity window.
The 5-HT7 receptor knockout mice oﬀer a comple-
mentary approach to classical pharmacology and might
provide insights into the functional implications of 5-
HT7 receptors. To date, data obtained with these mutants
suggest the involvement of 5-HT7 receptors in depression,
schizophrenia,sleep,learning,locomotion,andhypothermia
[25, 28, 34–37].
In this work, we demonstrated that sensitivity to noxious
heat measured as the latency time of response to thermal
stimulation in the tail ﬂick, tail immersion, and hot plate
tests did not diﬀer in 5-HT7 receptor knockout compared to
wild-type mice, as previously described [38]. In addition, the
formalin-induced nociceptive behavior of 5-HT7 receptor
knockout mice was not diﬀerent from wild-type mice as
no signiﬁcant diﬀerences in licking/biting time were found
between both genotypes, for either phase I or phase II of the
formalin test. These results suggest that basic mechanisms
for transduction, transmission, and perception of, as well as
response to, nociceptive stimuli are intact in mice lacking 5-
HT7 receptors. As previously reported, the loss of function of
the missing 5-HT7 receptor could induce possible adaptive
changes which could compensate for some alterations,
thereby resulting in wild-type-like responses [38–40].
Thermal nociception and early phase response in the
formalin test are caused predominantly by direct activation
of peripheral C-ﬁbers, whereas the late response (phase II)
in the formalin test involves functional changes in the dorsal
hornofthespinalcord(i.e.,centralsensitization)[41–43].In
this study, subcutaneous administration of 5-HT7 receptor
agonists was devoid of activity in acute nociceptive tests
(i.e., thermal- and formalin-induced phase I nociception),
but exerted clear-cut antinociceptive eﬀe c t si np h a s eI Io f
the formalin test in wild-type mice. These results are in line
with previous studies showing that 5-HT7 receptor agonists
and antagonists were ineﬀective in acute thermal nociceptive
pain [44–47]. The lack of antinociceptive eﬀects in thermal
and phase I formalin-induced nociception, observed when
5-HT7 receptor agonists were administered, suggests no
direct modulation by the 5-HT7 receptor subtype of acute
nociceptive signals coming from small caliber unmyelinated
nociceptive aﬀerents. However, activation of spinal 5-HT7
receptorshasbeenshowntoplayaroleintheantinociceptive
eﬀects of opioids [44–47].
Our results on phase II formalin-induced behavior are
in line with previous reports describing antinociceptive
eﬀects of selective 5-HT7 receptor agonists by systemic
or spinal administration in neurogenic and neuropathic
pain conditions involving central sensitization [13, 14, 17].
However, a clear-cut pronociceptive (proallodynic) eﬀect
was found when a 5-HT7 receptor agonist was adminis-
tered intraplantarly into the ipsilateral hind paw injected
with a low subactive dose of capsaicin [17]. In contrast,
data in the literature using the formalin test suggest a
pronociceptive role of both peripheral and spinal 5-HT7
receptors. Indeed, intraplantar or spinal administration of
5-carboxamidotryptamine, a nonselective 5-HT7 receptor
agonist, increased phase II formalin-induced nociceptive
behavior, and these eﬀects were signiﬁcantly reversed by
the selective 5-HT7 receptor antagonist SB-269970 [23].
Diﬀerences could be due to species (mice versus rats),
primary administration route (systemic versus spinal and
local peripheral), selectivity of the 5-HT7 agonists used and
animal models.
To further assess the in vivo speciﬁcity of the 5-HT7
receptor agonists used in this study, we examined in 5-HT7
receptor knockout mice, the eﬀects of the 5-HT7 receptor
agonists AS-19, E-57431, and E-55888 on both formalin-
induced nociception and body temperature. Under our
experimental conditions, 5-HT7 receptor agonists, at doses
eﬀective to reduce phase II formalin-induced nociceptive
behavior, aﬀected body temperature neither in wild-type
mice nor in 5-HT7 knockout mutants. However, AS-19
and E-57431 at the high dose of 20mg/kg signiﬁcantly
reduced body temperature not only in wild-type but also
in 5-HT7 receptor knockout mice, indicating a non-5-
HT7 receptor-mediated eﬀect possibly due to interactions
of these compounds with other 5-HT receptors when
their selectivity window is surpassed. In line with this
interpretation, we found that E-55888, the most selective 5-
HT7 receptor agonist based on in vitro radioligand binding
assays (Table 1), even at the dose of 20mg/kg, did not exert
any eﬀect on body temperature in both genotypes. Taken
together, the ﬁnding that the less selective agonists (AS-
19 and E-57431) at high doses reduced body temperature
in both wild-type and knockout mice, whereas the most
selective one (E-55888) did not, suggests that activation
of 5-HT7 receptors alone is not enough to aﬀect body
temperature. Our results do not rule out the possibility that
5-HT7 receptors might contribute to the regulation of body
temperature by acting in concert with other serotonergic
and/or nonserotonergic receptors. Indeed, we found a higher8 Advances in Pharmacological Sciences
hypothermic eﬀect induced by AS-19 (20mg/kg) in wild-
type compared to 5-HT7 receptor knockout mice, suggesting
that 5-HT7 receptors might promote the decrease in body
temperature when other mechanisms are also recruited. The
in vitro binding proﬁle of these ligands (see Table 1) suggests
that 5-HT1D and/or 5-HT1A receptors could be involved in
the observed hypothermic eﬀects of AS-19 and E-57431,
also because activation of these receptor types has been
reported to induce hypothermia [16, 28, 48]. Overall, as
previously reported, 5-HT7 receptors appear to be involved
inacomplexmanner inthermoregulation,probablythrough
mechanismsimplicatingdirect/indirectinteractionsbetween
5-HT7 receptors and other molecular targets.
5. Conclusions
Data obtained in this study strengthen the notion that 5-HT7
receptorsplayaroleinnociceptivecontrolinpainconditions
involving central sensitization and add further support to
their ﬁne-tuning eﬀects in body temperature homeostasis
throughpossibleactionsinconcertwithothermoleculartar-
gets. In addition, this study provides evidence that formalin-
induced nociceptive behaviors and body temperature in 5-
HT7 receptor knockout mice are useful models and relatively
simple approaches to assess in vivo speciﬁcity of 5-HT7
receptor agonists.
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